3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Carcinoma, Non-Small-Cell Lung
7
Neurofibromatosis 1
6
Neoplasm Metastasis
6
Solid Tumours
5
Neoplasms
5
Melanoma
5
Neurofibroma, Plexiform
4
Lung Neoplasms
3
Colorectal Neoplasms
3
Breast Neoplasms
2
Biliary Tract Neoplasms
2
Uveal Melanoma
1
Solid Tumors
1
Renal Insufficiency
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Muscle Invasive Bladder Cancer
1
Locally Advanced or Metastatic Solid Tumors
1
Kidney Neoplasms
1
Healthy Volunteers Pharmacokinetic Study
1
Disease Progression
1
Differentiated Thyroid Cancer
1
Colonic Neoplasms
1
Advanced Non Small Cell Lung Cancer
1
Advanced Cancer
1
Interventions
Thyrotropin Alfa
4
donafenib
2
Injections
2
vandetanib
1
anlotinib
1
Iodine-131
1
AZD 6244
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Differentiated Thyroid Cancer
×
AZD 6244
×
Clear all
NCT01843062
2019-08-28
ASTRA
AstraZeneca
Phase 3
Terminated
233 enrolled
14 charts